Literature DB >> 26629236

Refractory status epilepticus, serious rhabdomyolysis, acute liver injury, and pancytopenia after a massive intake of ethyl methanesulfonate: a case report.

Hiroyuki Yamazaki1, Shogo Tajima2, Takahiro Takeuchi3.   

Abstract

Ethyl methanesulfonate is a mutagenic, alkylating agent and considered harmful to humans at levels greater than a certain threshold; however, the toxicity at high doses remains unclear. We report a case of a Japanese man who presented with status epilepticus, rhabdomyolysis, pancytopenia, and hair loss after accidental ingestion of a massive amount of ethyl methanesulfonate. The patient completely recovered with critical care, including multiple antiepileptic drugs, renal replacement therapy, blood transfusion, granulocyte colony-stimulating factor therapy, and antibacterial/fungal prophylaxis. The case indicates that ethyl methanesulfonate causes neurotoxicity, hepatotoxicity, hematotoxicity, and renal toxicity, which can be successfully treated with appropriate palliative therapies.

Entities:  

Keywords:  Ethyl methanesulfonate; acute toxicity; pancytopenia; rhabdomyolysis; status epilepticus

Year:  2015        PMID: 26629236      PMCID: PMC4659124     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU.

Authors:  Elmar Gocke; Lutz Müller
Journal:  Mutat Res       Date:  2009-04-17       Impact factor: 2.433

2.  In vivo genotoxicity of EMS: statistical assessment of the dose response curves.

Authors:  Elmar Gocke; Michael Wall
Journal:  Toxicol Lett       Date:  2009-03-21       Impact factor: 4.372

Review 3.  Rhabdomyolysis: pathogenesis, diagnosis, and treatment.

Authors:  Patrick A Torres; John A Helmstetter; Adam M Kaye; Alan David Kaye
Journal:  Ochsner J       Date:  2015

4.  Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.

Authors:  G Vassal; A Deroussent; O Hartmann; D Challine; E Benhamou; D Valteau-Couanet; L Brugières; C Kalifa; A Gouyette; J Lemerle
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

5.  Relationships between ethylation of hemoglobin, ethylation of DNA and administered amount of ethyl methanesulfonate in the mouse.

Authors:  M S Murthy; C J Calleman; S Osterman-Golkar; D Segerbäck; K Svensson
Journal:  Mutat Res       Date:  1984-06       Impact factor: 2.433

6.  MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.

Authors:  Elmar Gocke; Mark Ballantyne; James Whitwell; Lutz Müller
Journal:  Toxicol Lett       Date:  2009-04-01       Impact factor: 4.372

7.  Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.

Authors:  Lutz Müller; Elmar Gocke; Thierry Lavé; Thomas Pfister
Journal:  Toxicol Lett       Date:  2009-04-10       Impact factor: 4.372

Review 8.  Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.

Authors:  Elmar Gocke; Heinrich Bürgin; Lutz Müller; Thomas Pfister
Journal:  Toxicol Lett       Date:  2009-03-28       Impact factor: 4.372

9.  Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.

Authors:  Eric J Bow; Michel Laverdière; Nathalie Lussier; Coleman Rotstein; Mary S Cheang; Stratis Ioannou
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

Review 10.  Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Authors:  Ana L Huerta-Alardín; Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2004-10-20       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.